High level of sBCMA may interfere with BCMA-targeted immunotherapy by reducing the total amount of cell-surface BCMA and sequestering circulating ligands or anti-BCMA antibodies, thereby inhibiting efficient binding to MM cells [65, 66]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.